The Journal of Headache and Pain

Official Journal of the "European Headache Federation" and of "Lifting The Burden - The Global Campaign against Headache"

The Journal of Headache and Pain Cover Image

Volume 15 Supplement 1

Abstracts from the 4th European Headache and Migraine Trust International Congress: EHMTIC 2014

Open Access

EHMTI-0379. Update of the uk post market pilot programme with single pulse transcranial magnetic stimulation (STMS) for the acute treatment of migraine

  • R Bhola1,
  • E Kinsella1,
  • F Ahmed2 and
  • PJ Goadsby3
The Journal of Headache and Pain201415(Suppl 1):M2

Published: 18 September 2014


MigraineTelephone SurveyChronic MigraineMigraine PatientPilot Programme


Some patients suffer disabling, frequent migraine without effective treatment as current pharmacological options may be contra-indicated, poorly tolerated or overused. Single pulse transcranial magnetic stimulation (sTMS) is a novel, CE marked, non-drug treatment for migraine.


To evaluate the patient response to sTMS in open outpatient settings at UK headache clinics, and to assess the impact of sTMS over three months.


Clinicians selected patients and prescribed the device. Migraine patients with and without aura treating with sTMS had an initial review and training call (n = 304) with a headache nurse and then participated in telephone surveys at week six (n = 157) and week twelve during a 3-month treatment period (n= 122; episodic, n = 42; chronic, n = 80). Patient outcomes were documented, anonymised and analyzed and are presented here.


In total 122 (35%) patients have been using the device for a minimum of three months and completed surveys. Of these, 89 (73%) reported a reduction or alleviation of pain. 101 (83%) were also using an acute medication at the time of prescription. Of these, 69 (68%) reported a reduction in the number of days of medications use. The treatment was well tolerated with no serious or unanticipated adverse events reported.


sTMS may be a valuable addition to options for the treatment of both episodic and chronic migraine. This device is safe to use in clinical practice and has reliable, reproducible effects on migraine over time.

The UK Pilot Programme was supported by eNeura Therapeutics.

Authors’ Affiliations

Clinical Research, eNeura Therapeutics, London, UK
Neurology, Hull and East Yorkshire NHS Hospitals Trust, Hull, UK
Headache Group - Clinical Neuroscience, NIHR Welcome Trust Clinical Research Facility Kings College London, London, UK


© Bhola et al; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.